Guillain-Barré Syndrome (Adult)

1. Clinical Overview

Guillain-Barré Syndrome (GBS) is an acute, post-infectious, immune-mediated polyneuropathy representing the most common cause of acute flaccid paralysis in the post-polio era. The syndrome encompasses a spectrum of disorders characterized by progressive, symmetric muscle weakness accompanied by areflexia, typically reaching nadir within 2-4 weeks of symptom onset. [1,2]

The fundamental pathophysiology involves molecular mimicry, whereby antibodies generated against infectious pathogens cross-react with peripheral nerve gangliosides, triggering immune-mediated damage to myelin sheaths or axons. This autoimmune assault disrupts nerve conduction, manifesting clinically as ascending paralysis with distinctive cerebrospinal fluid (CSF) findings of albuminocytologic dissociation. [3,4]

While approximately 85% of patients achieve functional recovery, GBS carries significant morbidity and a mortality rate of 3-7% despite modern intensive care, primarily due to respiratory failure, autonomic dysfunction, and thromboembolic complications. Early recognition and prompt immunotherapy with intravenous immunoglobulin (IVIg) or plasma exchange are critical to improving outcomes. [5,6]

Key Clinical Messages

For Diagnosis:

• Areflexia is the diagnostic hallmark; preserved or brisk reflexes virtually exclude GBS
• Look for ascending, symmetric weakness progressing over days to weeks (not hours)
• Respiratory muscle involvement occurs in 25-30% and requires vigilant monitoring
• CSF albuminocytologic dissociation appears after the first week in 80-90% of cases

For Management:

• Forced vital capacity (FVC) monitoring is mandatory, not pulse oximetry
• IVIg and plasma exchange are equally effective; combining them provides no benefit
• Corticosteroids are ineffective and potentially harmful—do not use
• ICU admission is indicated for bulbar dysfunction, respiratory compromise, or severe autonomic instability

For Prognosis:

• Poor prognostic factors: advanced age, rapid progression, preceding diarrheal illness (Campylobacter), low distal compound muscle action potential amplitudes, need for mechanical ventilation
• 5-10% develop chronic inflammatory demyelinating polyneuropathy (CIDP)—the chronic relapsing variant

---

2. Epidemiology

Incidence and Prevalence

Guillain-Barré Syndrome exhibits a worldwide distribution with remarkably consistent incidence across diverse populations and geographic regions. The annual incidence ranges from 0.81 to 1.89 per 100,000 population, with most studies converging around 1.1-1.8 cases per 100,000. [7,8] Unlike many autoimmune conditions, GBS does not demonstrate significant seasonal variation, although minor peaks following respiratory virus seasons have been reported in some cohorts.

Demographic Patterns

Age Distribution: GBS demonstrates a bimodal age distribution, with peaks in young adults (15-35 years) and older adults (50-75 years). Incidence increases progressively with age, with individuals over 60 years experiencing nearly double the risk compared to younger populations. Advanced age is also associated with worse outcomes and prolonged recovery. [7,9]

Sex Distribution: Males are affected approximately 1.5 times more frequently than females, a pattern consistent across all age groups and geographic regions. The biological basis for this sex difference remains unclear but may relate to differential immune responses or exposure patterns to triggering infections. [8]

Geographic Variation: While overall incidence is similar globally, the relative frequencies of GBS variants differ geographically. Acute inflammatory demyelinating polyneuropathy (AIDP) predominates in North America and Europe (85-90% of cases), whereas acute motor axonal neuropathy (AMAN) accounts for 30-65% of cases in Asia, particularly in China, Japan, and Bangladesh. [11,12]

Antecedent Infections and Triggers

Approximately 60-70% of GBS cases are preceded by an identifiable infection occurring 1-4 weeks before neurological symptom onset. [13] The most commonly implicated pathogens include:

Gastrointestinal Pathogens:

• Campylobacter jejuni (25-40% of cases): The most frequently identified trigger, particularly associated with axonal variants (AMAN, AMSAN) and poorer prognosis. Specific serotypes (e.g., HS:19, HS:41) expressing GM1-like lipo-oligosaccharides demonstrate strongest associations. [14,15]
• Salmonella species, Shigella, Helicobacter pylori: Less common bacterial triggers

Respiratory Viruses:

• Cytomegalovirus (CMV): 10-22% of cases, often associated with severe disease and cranial nerve involvement
• Epstein-Barr virus (EBV): 2-10% of cases
• Influenza A and B: Seasonal association
• Mycoplasma pneumoniae: Particularly in children and young adults [13,16]

Emerging Viral Pathogens:

• Zika virus: 2015-2016 epidemics in French Polynesia and Latin America demonstrated strong temporal associations, with incidence increases up to 20-fold during outbreaks. [17,18]
• SARS-CoV-2 (COVID-19): Case reports suggest possible association, though definitive epidemiological links remain under investigation
• Dengue, Chikungunya: Reported in endemic regions

Vaccinations: Historical associations with swine flu vaccine (1976) led to heightened vigilance, but modern vaccines carry minimal risk. The absolute risk following influenza vaccination is approximately 1-2 per 1,000,000 doses, substantially lower than the risk of GBS following influenza infection itself (4-7 per 1,000,000 infections). [19,20] No convincing evidence links routine vaccinations (MMR, DTP, HPV, COVID-19) to increased GBS risk.

---

3. Aetiology and Pathophysiology

Molecular Mimicry: The Core Mechanism

Guillain-Barré Syndrome exemplifies post-infectious autoimmunity driven by molecular mimicry, wherein structural similarities between microbial antigens and host peripheral nerve components trigger cross-reactive immune responses. [3,4]

The Cascade:

1. Infection: Pathogen exposure (e.g., Campylobacter jejuni) induces antibody production against microbial surface structures
2. Cross-Reactivity: Bacterial lipo-oligosaccharides structurally resemble human gangliosides (complex glycolipids) embedded in peripheral nerve myelin and axolemma
3. Autoantibody Formation: Anti-ganglioside antibodies (IgG, IgA classes) target peripheral nerve components
4. Immune Attack: Antibody binding activates complement cascades and recruits macrophages, leading to:
   • Myelin destruction (demyelinating variants)
   • Direct axonal injury (axonal variants)
   • Node of Ranvier disruption
5. Conduction Failure: Segmental demyelination or axonal degeneration impairs saltatory conduction, manifesting as weakness and areflexia

Gangliosides and Antibody Specificity

Gangliosides are sialic acid-containing glycosphingolipids concentrated at nodes of Ranvier and neuromuscular junctions. Specific anti-ganglioside antibody profiles correlate with clinical variants:

Anti-GM1 antibodies are detected in 20-50% of AMAN cases and 10-20% of AIDP cases, particularly those with preceding Campylobacter infection. Anti-GQ1b antibodies are found in > 85% of Miller Fisher Syndrome cases, providing high diagnostic specificity. [21,22]

GBS Variants: Pathological Subtypes

1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)

The classic and most common variant in Western populations (85-90% of North American/European cases). Pathologically characterized by:

• Segmental demyelination with inflammatory infiltrates
• Endoneurial macrophages stripping myelin lamellae
• Relative axonal preservation (initially)
• Demyelinating features on nerve conduction studies
• Generally favorable prognosis with remyelination potential [11,12]

2. Acute Motor Axonal Neuropathy (AMAN)

Predominantly axonal injury without significant demyelination:

• Direct antibody-mediated attack on axolemma at nodes of Ranvier
• Macrophage infiltration with axonal degeneration
• Predominantly motor involvement (motor nerves more susceptible)
• Common in Asia (30-65% of Chinese/Japanese cases)
• Strong association with Campylobacter jejuni
• Variable prognosis; severe cases require axonal regeneration (slow, incomplete) [11,12,23]

3. Acute Motor and Sensory Axonal Neuropathy (AMSAN)

Severe variant with combined motor and sensory axonal degeneration:

• Pathological features similar to AMAN but involving sensory fibers
• More extensive complement-mediated axonal destruction
• Poorest prognosis among GBS subtypes
• High rates of residual disability
• Often requires prolonged mechanical ventilation [24]

4. Miller Fisher Syndrome (MFS)

Distinct clinical phenotype accounting for approximately 5% of GBS cases in Western populations, up to 25% in Asian populations:

• Triad: ophthalmoplegia, ataxia, areflexia
• Anti-GQ1b antibodies in > 85% of cases (GQ1b enriched in oculomotor nerves)
• Self-limited course; rarely requires immunotherapy
• Excellent prognosis; complete recovery typical within 3-6 months [25,26]

5. Pharyngeal-Cervical-Brachial Variant

Rare localized form characterized by:

• Selective weakness of oropharyngeal, neck, and shoulder muscles
• Anti-GT1a antibodies frequently detected
• Bulbar dysfunction without limb weakness
• Lower extremities spared
• High risk of aspiration; respiratory support often needed [27]

6. Bickerstaff Brainstem Encephalitis

Overlap syndrome sharing features with Miller Fisher but including:

• Altered consciousness and brainstem signs
• Hyperreflexia (distinguishing from classic GBS)
• Anti-GQ1b antibodies
• MRI may show brainstem signal changes
• Considered part of GBS-MFS-BBE spectrum [28]

Complement Activation and Nerve Injury

Recent mechanistic studies emphasize the critical role of complement-mediated nerve injury, particularly in axonal variants. Antibody binding to gangliosides at nodes of Ranvier activates the classical complement pathway, leading to:

• Membrane attack complex (MAC) formation on axolemma
• Direct axonal membrane disruption
• Macrophage recruitment and phagocytosis
• Paranodal myelin detachment and nodal lengthening [4,29]

This complement-dependent mechanism explains the efficacy of IVIg (which neutralizes complement) and plasma exchange (which removes antibodies).

---

4. Clinical Presentation

Cardinal Features

Guillain-Barré Syndrome classically presents with the triad of:

1. Progressive, symmetric weakness (mandatory criterion)
2. Areflexia (present in > 90% at nadir)
3. Symptoms progressing over days to weeks (not hours)

Temporal Pattern

Phase 1: Progression Phase (Days 0-14, up to 28)

• Weakness begins distally in lower limbs and ascends
• Peak deficit ("nadir") reached within 2 weeks in 50%, within 4 weeks in 90%
• Rapid progression (less than 24 hours to nadir) suggests severe disease and higher ventilation risk

Phase 2: Plateau Phase (Days 14-28)

• Stable deficits without further progression
• Duration varies (days to weeks)
• Critical period for respiratory and autonomic complications

Phase 3: Recovery Phase (Weeks 4-52+)

• Gradual improvement following descent pattern (reversal of ascent)
• Proximal muscles often recover before distal
• Complete recovery in 60-80% by 1 year
• Residual deficits persist in 20-30%

Motor Manifestations

Pattern of Weakness:

• Symmetric: Bilateral involvement is the rule; unilateral weakness should prompt reconsideration of diagnosis
• Ascending: Classic pattern starts in toes/feet → legs → hands/arms → trunk → cranial nerves
• Proximal and distal: Unlike many neuropathies, GBS affects both proximal and distal muscles
• Flaccid paralysis: Lower motor neuron pattern with hypotonia

Distribution:

• Lower limbs affected first in > 80% of cases
• Upper limbs involved in moderate-to-severe cases
• Facial weakness (bilateral LMN CN VII) in 50%
• Bulbar muscles (CN IX, X, XII) in 10-30%, portending respiratory compromise
• Respiratory muscles (diaphragm, intercostals) in 25-30% [30,31]

Examination Findings:

• Power: Reduced globally; often symmetric Medical Research Council (MRC) grades
• Tone: Flaccid (reduced)
• Reflexes: Absent or markedly diminished (early and universal)
• Gait: High-steppage gait (foot drop) → unable to walk without assistance → wheelchair/bedbound

Sensory Manifestations

Sensory symptoms are common but typically less prominent than motor deficits:

Positive Sensory Symptoms:

• Paresthesias: Distal "glove and stocking" tingling, numbness (60-80% of patients)
• Neuropathic pain: Deep, aching pain in back, thighs, and calves (50-70%)
  • Often severe enough to require opioid analgesia
  • May precede weakness by days
  • Underrecognized and undertreated [32,33]

Objective Sensory Loss:

• Mild distal impairment of vibration and joint position sense
• Pain and temperature sensation relatively preserved
• Critical distinction: Presence of a sensory level (e.g., T10 dermatomal level) excludes GBS and suggests myelopathy—requires urgent spinal imaging

Proprioceptive Ataxia:

• Loss of joint position sense leads to sensory ataxia (particularly in AMAN and Miller Fisher variants)
• Positive Romberg sign
• Unsteady gait even without significant weakness

Cranial Nerve Involvement

Cranial neuropathies develop in 45-75% of patients, typically appearing after limb weakness:

Bilateral facial weakness with preserved eye movements is highly characteristic of GBS (distinguishing from brainstem lesions which typically cause unilateral facial weakness with eye movement abnormalities). [34]

Autonomic Dysfunction: The "Silent Killer"

Autonomic involvement occurs in 60-70% of GBS patients and accounts for significant morbidity and mortality. Manifestations range from mild to life-threatening. [35,36]

Cardiovascular:

• Cardiac arrhythmias: Sinus tachycardia most common; bradycardia, heart block, asystole (rare but fatal)
• Labile blood pressure: Wide fluctuations between hypertension and hypotension
• Orthostatic hypotension: Postural BP drops > 20/10 mmHg
• Sudden cardiac death: Reported in 2-10% of ICU patients; often during tracheal suctioning (vagal stimulation)

Urinary:

• Urinary retention (10-30%): Often transient; catheterization required
• Detrusor hyperreflexia or hyporeflexia

Gastrointestinal:

• Ileus: Delayed gastric emptying, constipation
• Diarrhea or constipation: Pre-existing (from infection) or new-onset

Sudomotor:

• Excessive sweating or anhidrosis
• Flushing

Pupillary:

• Abnormal pupillary light reflexes (uncommon but described)

Key Clinical Pearl: Autonomic dysfunction requiring ICU management is more common in patients with:

• Rapid progression
• Severe motor deficits
• Bulbar involvement
• Older age Continuous cardiac monitoring is mandatory in all hospitalized GBS patients. [35,36]

Respiratory Involvement

Respiratory muscle weakness develops in approximately 25-30% of GBS patients and represents the leading cause of ICU admission and mortality. [37,38]

Risk Factors for Respiratory Failure:

• Time from symptom onset to admission less than 7 days
• Inability to cough (bulbar dysfunction)
• Inability to stand
• Inability to lift elbows or head off bed
• Elevated liver transaminases (marker of disease severity)
• Bilateral facial weakness
• Dysautonomia

Clinical Signs of Respiratory Compromise:

• Tachypnea (RR > 30/min)
• Accessory muscle use
• Paradoxical abdominal breathing
• Inability to count to 20 in a single breath ("single breath count" less than 15)
• Weak cough
• Orthopnea

Objective Measures:

• Forced Vital Capacity (FVC): Serial measurements essential
  • "FVC less than 20 mL/kg: High risk; consider elective intubation"
  • "FVC less than 15 mL/kg: Intubation typically required"
• Negative Inspiratory Force (NIF): < -30 cmH₂O indicates weakness
• Arterial Blood Gas (ABG): Rising PaCO₂ is a LATE sign; do not wait for hypercapnia

Critical Concept: Pulse oximetry is a late and unreliable marker of respiratory compromise in GBS. Oxygen saturation remains normal until severe hypoventilation occurs. FVC monitoring is the gold standard for detecting impending respiratory failure. [37,38]

Atypical and Variant Presentations

Miller Fisher Syndrome:

• Triad: Ophthalmoplegia, ataxia, areflexia
• Descending pattern (cranial → limbs) rather than ascending
• Limb weakness absent or mild
• Anti-GQ1b antibodies in > 85%
• Self-limited; excellent prognosis [25,26]

Pharyngeal-Cervical-Brachial Variant:

• Weakness restricted to oropharyngeal, neck, and arm muscles
• Lower limbs spared
• High aspiration risk
• Anti-GT1a antibodies [27]

Paraparetic Variant:

• Weakness limited to legs
• Arms spared
• Less common
• Generally milder course

Sensory GBS:

• Extremely rare
• Predominant sensory ataxia with areflexia
• Minimal motor involvement
• Anti-GD1b antibodies

---

5. Differential Diagnosis

Acute flaccid paralysis has a broad differential diagnosis. Distinguishing GBS from mimics is critical to avoid delayed diagnosis and treatment.

Key Differentiating Features

Diagnostic Red Flags Suggesting Alternative Diagnosis

❌ Exclude GBS if:

• Sensory level present (suggests myelopathy)
• Preserved or hyperactive reflexes (UMN pathology)
• Asymmetric weakness (consider stroke, myelopathy, focal neuropathy)
• Progression to nadir > 8 weeks (consider CIDP)
• Marked CSF pleocytosis (> 50 cells/µL) in non-HIV patient (suggests infection, malignancy)
• Bladder/bowel dysfunction early and prominent (suggests cauda equina or myelopathy)
• Purely motor with fasciculations (consider motor neuron disease)

Must-Not-Miss Differentials

1. Spinal Cord Compression (Surgical Emergency):

• Back pain, sensory level, sphincter dysfunction
• Hyperreflexia below level of lesion
• Action: Urgent MRI spine within hours

2. Brainstem Stroke:

• Sudden onset (not progressive over days)
• Cranial nerve palsies with crossed signs (ipsilateral CN, contralateral limb)
• UMN signs
• Action: Urgent CT/MRI brain, stroke protocol

3. Myasthenia Crisis:

• Fluctuating weakness, fatiguability
• Ophthalmoparesis, ptosis, bulbar symptoms
• Action: Edrophonium test, anti-AChR antibodies, neostigmine trial

4. Botulism:

• Descending paralysis (eyes → face → bulbar → limbs)
• Fixed dilated pupils (pathognomonic)
• Action: Food history, stool/serum for botulinum toxin, antitoxin administration

---

6. Investigations

The diagnosis of Guillain-Barré Syndrome is primarily clinical, supported by characteristic cerebrospinal fluid (CSF) findings and nerve conduction studies (NCS). No single test is pathognomonic; diagnosis relies on the constellation of clinical features and investigation results.

Brighton Criteria for GBS Diagnosis

The Brighton Collaboration established standardized diagnostic criteria for post-vaccination surveillance, widely adopted for clinical diagnosis:

Level 1 Certainty (Highest):

• Bilateral flaccid limb weakness
• Decreased/absent deep tendon reflexes
• Monophasic illness pattern
• Time to peak weakness 12 hours to 28 days, followed by plateau
• CSF albuminocytologic dissociation (elevated protein, WCC less than 50 cells/µL)
• NCS findings consistent with GBS
• Absence of alternative diagnosis

Required Features:

• Progressive, relatively symmetric weakness
• Areflexia or hyporeflexia
• Duration of progression 4 hours to 4 weeks
• Absence of other causes [39]

Cerebrospinal Fluid Analysis

Lumbar puncture is essential for diagnosis, revealing the hallmark finding of albuminocytologic dissociation: elevated CSF protein with normal or minimally elevated white cell count.

Classic CSF Findings in GBS:

Important Caveats:

• Timing matters: CSF protein may be normal in the first 3-7 days of illness. If clinical suspicion is high and initial LP is normal, repeat LP at 1 week.
• Absence does not exclude: 10-20% of GBS patients have normal CSF protein even at nadir
• HIV exception: Patients with HIV-associated GBS may have CSF pleocytosis (10-50 cells/µL) without excluding the diagnosis [40,41]

Differential Diagnosis Based on CSF:

Nerve Conduction Studies (NCS) and Electromyography (EMG)

Neurophysiological studies confirm the diagnosis, classify the subtype (demyelinating vs. axonal), and provide prognostic information. However, NCS may be normal in the first week of illness. [42,43]

Timing of NCS:

• Week 1: Normal or minimal abnormalities in 30-50%
• Week 2-3: Abnormalities evolve; definitive subtype classification possible
• Weeks 3-6: Peak abnormalities; prognosis assessment

Demyelinating Features (AIDP):

• Prolonged distal motor latencies (> 110-125% of upper limit of normal)
• Conduction velocity slowing (less than 90% of lower limit of normal)
• Conduction block (> 50% drop in amplitude between proximal and distal stimulation)
• Temporal dispersion (prolongation of waveform duration > 30%)
• F-wave prolongation or absence (early finding; reflects proximal nerve involvement)

Axonal Features (AMAN, AMSAN):

• Reduced compound muscle action potential (CMAP) amplitudes
• Normal or near-normal conduction velocities
• No conduction block or temporal dispersion
• Sensory nerve action potentials (SNAPs) preserved in AMAN, reduced in AMSAN
• F-waves absent or prolonged

Prognostic Value:

• Low CMAP amplitudes (less than 20% of normal) predict poor outcome and prolonged recovery
• Absence of F-waves correlates with disease severity
• Axonal loss (low amplitudes) indicates longer recovery than pure demyelination [42,43]

EMG Findings:

• Acute denervation (fibrillation potentials, positive sharp waves) appears after 2-3 weeks
• Indicates axonal loss
• Reduced recruitment of motor units
• EMG is complementary to NCS but not required for diagnosis

Anti-Ganglioside Antibody Testing

Detection of anti-ganglioside antibodies supports the diagnosis and classifies the subtype, though sensitivity is limited (positive in 30-60% overall). [21,22]

Interpretation:

• Positive antibodies confirm diagnosis but are not required (low sensitivity)
• Negative antibodies do not exclude GBS
• Anti-GQ1b is highly specific for Miller Fisher Syndrome
• Antibody levels do not correlate with disease severity or guide treatment

Respiratory Function Monitoring

Serial bedside spirometry is mandatory for all GBS patients to detect impending respiratory failure before clinical decompensation. [37,38]

Essential Monitoring:

The 20/30/40 Rule:

• FVC less than 20 mL/kg → Consider ICU transfer
• NIF < -30 cmH₂O → Consider intubation
• PaO₂ less than 40 mmHg (FiO₂ 0.21) → Hypoxemic failure

Single Breath Count: A simple bedside test: ask patient to take a deep breath and count aloud as high as possible. If unable to reach 15, FVC is likely less than 1L and intubation is imminent. [38]

Microbiological Investigations

Identify preceding infections to guide supportive management and epidemiology:

Recommended Tests:

• Stool culture: Campylobacter jejuni (if diarrhea or within 4 weeks)
• Serology:
  • CMV IgM/IgG
  • EBV VCA IgM/IgG
  • Mycoplasma pneumoniae IgM
  • Zika virus RT-PCR/IgM (if travel to endemic area)
• Respiratory viral panel: Influenza, RSV (if respiratory symptoms)

Clinical Utility:

• Identifies trigger (epidemiological interest)
• Campylobacter-associated cases have worse prognosis (axonal injury)
• No change in acute management (immunotherapy is the same)
• Public health reporting for Zika-associated cases

Other Laboratory Investigations

Baseline Blood Tests:

• Full blood count (FBC): Exclude leukemia/lymphoma causing neuropathy
• Electrolytes (U&E): Hypokalemia/hypophosphatemia can mimic GBS
• Liver function tests (LFTs): Elevated transaminases correlate with disease severity
• Creatine kinase (CK): Exclude myositis (elevated in muscle disease, normal/mild elevation in GBS)
• HIV serology: Especially if CSF pleocytosis present
• Vitamin B12: Exclude subacute combined degeneration
• Thyroid function: Hypothyroidism can cause neuropathy

Autoimmune Screen (if atypical features):

• ANA, ENA, ANCA: Vasculitic neuropathy
• Anti-AChR, anti-MuSK: Myasthenia gravis
• Porphobilinogen (urine): Acute intermittent porphyria

Imaging Studies

MRI Spine: Not routinely required for typical GBS presentation, but indicated if:

• Sensory level present (exclude myelopathy)
• Back pain prominent
• Sphincter involvement early
• Asymmetric weakness
• Preserved/brisk reflexes (UMN signs)

MRI Brain: Indicated if:

• Cranial nerve palsies with UMN signs (brainstem lesion)
• Altered consciousness (Bickerstaff brainstem encephalitis)
• Atypical progression

MRI Findings in GBS (if performed):

• Spinal nerve root enhancement on T1 post-gadolinium (cauda equina enhancement)
• Seen in 50-95% of cases with contrast MRI
• Supportive but not diagnostic
• Also seen in CIDP, CMT, lymphoma [44]

Diagnostic Criteria Summary

Supportive Features:

• Progression over days to 4 weeks
• Relative symmetry
• Mild sensory symptoms/signs
• Cranial nerve involvement (especially bilateral facial weakness)
• Autonomic dysfunction
• Absence of fever at onset
• Recovery beginning 2-4 weeks after progression stops
• CSF albuminocytologic dissociation
• NCS features consistent with GBS

Features Against GBS:

• Marked asymmetry
• Persistent bladder/bowel dysfunction

• 50 WBCs/µL in CSF (non-HIV patient)

• Polymorphonuclear cells in CSF
• Sensory level
• Recent history of hexacarbon solvent abuse (toxic neuropathy)
• Abnormal porphyrin metabolism
• Definite diagnosis of other cause

---

7. Classification and Grading

Clinical Severity Grading: GBS Disability Scale

The modified Rankin Scale adapted for GBS (Hughes Functional Grading Scale) is the most widely used tool for assessing disability and guiding treatment decisions. [45]

Treatment Threshold: Immunotherapy (IVIg or plasma exchange) is indicated for patients with Hughes grade ≥3 (unable to walk 5 meters independently). Mild cases (grades 1-2) may be observed, though some centers treat grade 2 if rapidly progressing. [46]

Prognostic Scoring: Erasmus GBS Outcome Score (EGOS)

A validated prognostic model predicting inability to walk independently at 6 months. [47]

Predictors (assessed at 2 weeks):

• Age > 60 years: +1 point
• Preceding diarrhea: +1 point
• Hughes grade 5 (ventilated) at 2 weeks: +2 points

Clinical Application: Identifies patients needing intensive rehabilitation and realistic prognostic counseling. [47]

Modified Erasmus GBS Respiratory Insufficiency Score (EGRIS)

Predicts the need for mechanical ventilation. [48]

Risk Factors (assessed at admission):

• Days from symptom onset to admission less than 7 days: +2 points
• Facial weakness: +2 points
• Bulbar weakness: +1 point
• Unable to stand: +3 points
• Unable to lift elbows: +1 point
• Unable to lift head: +1 point

Clinical Application: Scores ≥5 warrant ICU admission for close respiratory monitoring. [48]

---

8. Management

Management of Guillain-Barré Syndrome requires multidisciplinary care encompassing immunotherapy, respiratory support, autonomic monitoring, and prevention of complications. Early treatment improves outcomes. [5,6,46]

General Principles

1. Early recognition and admission: All suspected GBS patients require hospital admission for monitoring
2. ICU triage: Admit to ICU/HDU if:
   • Bulbar dysfunction
   • FVC less than 20 mL/kg or declining
   • Hughes grade ≥4
   • Autonomic instability
   • Rapid progression
3. Immunotherapy: Start within 2 weeks of symptom onset (ideally within 7 days)
4. Supportive care: Prevent complications (VTE, pressure ulcers, contractures)
5. Rehabilitation: Initiate early physiotherapy

Immunotherapy: First-Line Treatment

Two equally effective immunotherapies exist: intravenous immunoglobulin (IVIg) and plasma exchange (PLEX). Combining them provides no additional benefit and is not recommended. [46,49,50]

Intravenous Immunoglobulin (IVIg)

Indications:

• Hughes grade ≥3 (unable to walk 5 meters independently) OR
• Rapidly progressive disease (grade 2 → 3 within 24-48 hours)

Dosing:

• Total dose: 2 g/kg divided over 5 days
• Regimen: 0.4 g/kg/day for 5 consecutive days
• Example: 70 kg patient = 140g total = 28g daily × 5 days

Mechanism of Action:

• Saturates neonatal Fc receptors, reducing pathogenic IgG recycling
• Neutralizes autoantibodies via anti-idiotypic antibodies
• Modulates complement activation
• Downregulates macrophage phagocytosis

Evidence Base: The Dutch GBS Study Group trial (1992) demonstrated equivalent efficacy between IVIg and plasma exchange, establishing IVIg as standard therapy. Subsequent meta-analyses confirm significant improvement in disability grade at 4 weeks. [49,50]

Advantages of IVIg:

• Ease of administration (peripheral IV access)
• Widely available
• No risk of hemodynamic instability
• No need for central venous access
• Fewer contraindications

Adverse Effects:

• Common: Headache (30-50%), fever, chills, nausea
• Uncommon: Aseptic meningitis, rash, arthralgia
• Rare but serious:
  • Thromboembolic events (stroke, MI, PE) — 1-5%
  • Acute renal failure (osmotic nephropathy from sucrose/maltose stabilizers)
  • Hemolytic anemia (if contains anti-A/B antibodies)
  • Anaphylaxis (IgA-deficient patients with anti-IgA antibodies)

Contraindications:

• Relative: IgA deficiency with anti-IgA antibodies (use IgA-depleted product)
• Relative: Severe renal impairment (choose low-osmolality product)
• Relative: Hypercoagulable states (consider prophylactic anticoagulation)

Monitoring:

• Baseline renal function, FBC, coagulation
• Infusion rate: Start slow (0.01-0.02 mL/kg/min), increase if tolerated
• Monitor for infusion reactions
• Ensure adequate hydration

Plasma Exchange (Plasmapheresis, PLEX)

Indications:

• Same as IVIg (Hughes grade ≥3)
• Preferred if IVIg contraindicated or unavailable

Dosing:

• 5 exchanges over 10-14 days (alternate days)
• Volume per exchange: 40-50 mL/kg (approximately 200-250 mL/kg total over 5 sessions)
• Replacement fluid: Albumin 5% or FFP (if coagulopathic)

Mechanism of Action:

• Directly removes circulating pathogenic antibodies (anti-ganglioside IgG)
• Removes complement components
• Reduces inflammatory cytokines

Evidence Base: French Cooperative Group trial (1997) and Cochrane meta-analyses demonstrate that plasma exchange accelerates recovery and reduces time on mechanical ventilation compared to supportive care alone. Equivalent to IVIg. [51,52]

Advantages of Plasma Exchange:

• Effective in IVIg non-responders (though evidence limited)
• May have faster onset of action (antibodies removed immediately vs. neutralized with IVIg)

Disadvantages:

• Requires central venous access (internal jugular or femoral line)
• Labor-intensive (trained apheresis staff required)
• Hemodynamic instability (fluid shifts)
• Electrolyte disturbances (hypocalcemia, hypomagnesemia)
• Infection risk (central line)
• Not available in all centers

Adverse Effects:

• Hypotension (volume depletion)
• Arrhythmias (electrolyte shifts)
• Bleeding (coagulation factor removal if albumin replacement used)
• Infection (catheter-related bloodstream infection)
• Allergic reactions (citrate toxicity, FFP reactions)

Contraindications:

• Hemodynamic instability unresponsive to resuscitation
• Severe coagulopathy (relative; can use FFP replacement)
• Inability to obtain vascular access

Comparison: IVIg vs. Plasma Exchange

Clinical Decision: IVIg is first-line in most centers due to ease and availability. Plasma exchange reserved for:

• IVIg unavailable
• IVIg contraindicated
• Severe disease requiring aggressive therapy (some evidence for benefit in ventilated patients, though not definitive) [53]

Treatment of Refractory or Severe GBS

Second Course of Immunotherapy: If no improvement or deterioration after first course (IVIg or PLEX), consider:

• Second course of IVIg (2 g/kg): Small studies suggest benefit in 30-50%
• Plasma exchange if IVIg used initially (or vice versa): No robust evidence but sometimes attempted

Corticosteroids: DO NOT USE Multiple high-quality RCTs and Cochrane meta-analyses consistently demonstrate:

• No benefit of oral or IV corticosteroids (methylprednisolone) in GBS
• Possible harm (delayed recovery, increased infection risk)
• Adding steroids to IVIg provides no additional benefit
• Exception: Miller Fisher Syndrome often recovers without treatment; steroids still not indicated [54,55]

Emerging Therapies (Investigational):

• Eculizumab (complement C5 inhibitor): Small case series; phase 2/3 trials ongoing
• IVIg + methylprednisolone combination: Japanese trial showed no benefit over IVIg alone [56]

Respiratory Support

Respiratory failure is the leading cause of mortality and ICU admission. Proactive management is essential. [37,38]

Monitoring

Serial Bedside Spirometry:

• FVC every 4-6 hours during progression phase
• NIF (negative inspiratory force) every 4-6 hours
• Single breath count each nursing shift

Arterial Blood Gas:

• Baseline ABG
• Repeat if clinical deterioration or FVC less than 20 mL/kg
• Rising PaCO₂ indicates hypoventilation (LATE sign)

Indications for Intubation

Absolute Indications:

• FVC less than 15 mL/kg or less than 1 L
• NIF >-30 cmH₂O (less negative)
• Hypoxemia (PaO₂ less than 60 mmHg on room air) or hypercarbia (PaCO₂ > 50 mmHg)
• Inability to clear secretions
• Aspiration

Relative Indications (Consider Elective Intubation):

• FVC less than 20 mL/kg and declining
• Bulbar dysfunction with risk of aspiration
• Severe autonomic instability
• Rapid progression

Intubation Strategy:

• Elective, controlled intubation preferred over emergency crash intubation
• Rapid sequence induction with caution:
  • "Avoid succinylcholine (depolarizing paralytic): Risk of hyperkalemia due to denervation hypersensitivity"
  • Use non-depolarizing agent (rocuronium, vecuronium)
• Prepare for difficult airway (bulbar weakness may impair mask ventilation)
• Monitor for vagal responses (bradycardia, asystole) during laryngoscopy

Mechanical Ventilation Management

Ventilator Settings:

• Lung-protective strategies (tidal volume 6-8 mL/kg ideal body weight)
• PEEP 5-8 cmH₂O
• Avoid high plateau pressures (less than 30 cmH₂O)

Duration:

• Median duration: 14-21 days
• Prolonged ventilation (> 30 days) in 30-40% of ventilated patients
• Tracheostomy typically performed if ventilation expected > 14-21 days

Weaning:

• Spontaneous breathing trials when:
  • FVC > 15-20 mL/kg
  • NIF < -30 cmH₂O
  • Clinical improvement evident (muscle strength improving)
• Gradual weaning; may take weeks

Complications of Ventilation:

• Ventilator-associated pneumonia (VAP): 30-50% of ventilated GBS patients
• Barotrauma
• Delirium
• Critical illness polyneuropathy/myopathy (superimposed on GBS)

Autonomic Dysfunction Management

Autonomic instability is unpredictable and potentially fatal. Continuous monitoring and judicious pharmacological intervention are required. [35,36]

Cardiovascular Monitoring

All GBS patients:

• Continuous cardiac telemetry
• Automatic BP monitoring every 15-60 minutes (adjust based on stability)
• Watch for labile BP (wide fluctuations)

High-risk patients (ICU):

• Invasive arterial line if severe autonomic dysfunction
• Central venous access for vasoactive drugs

Management of Specific Autonomic Manifestations

Bradycardia/Asystole:

• Prevention: Minimize vagal stimulation (tracheal suctioning, repositioning)
• Treatment:
  • Atropine 0.5-1 mg IV for symptomatic bradycardia
  • Temporary pacing if recurrent asystole or high-grade AV block
• Avoid: Beta-blockers (may precipitate asystole)

Tachycardia:

• Often benign (sympathetic surge)
• Exclude other causes (pain, anxiety, hypovolemia, PE)
• Avoid beta-blockers unless persistent and symptomatic (risk of sudden bradycardia)

Hypertension:

• Often paroxysmal; avoid aggressive treatment
• Short-acting agents if treatment needed (labetalol, hydralazine)
• Avoid long-acting agents (risk of sudden hypotension)

Hypotension:

• Fluid resuscitation first (hypovolemia common)
• Vasopressors if refractory (norepinephrine preferred)
• Avoid large fluid boluses (risk of pulmonary edema)

Orthostatic Hypotension:

• Gradual mobilization
• Compression stockings
• Increase salt/fluid intake
• Fludrocortisone 0.1-0.2 mg daily (if persistent)

Urinary Retention:

• Intermittent catheterization preferred over indwelling catheter (reduce infection risk)
• Indwelling catheter if unable to cooperate or severe retention
• Alpha-blockers (tamsulosin) may help if detrusor-sphincter dyssynergia

Ileus:

• Nasogastric decompression if severe
• Prokinetics (metoclopramide, erythromycin)
• Parenteral nutrition if prolonged

Supportive Care and Complication Prevention

Venous Thromboembolism (VTE) Prophylaxis

GBS patients have high VTE risk (10-25% without prophylaxis) due to immobility and hypercoagulable state. [57]

Pharmacological Prophylaxis:

• LMWH (enoxaparin 40 mg SC daily or dalteparin 5000 units SC daily)
• Start on admission unless contraindicated (active bleeding, severe thrombocytopenia)
• Continue until ambulatory

Mechanical Prophylaxis:

• Graduated compression stockings (TED stockings)
• Intermittent pneumatic compression devices (if unable to use stockings)

Surveillance:

• Clinical examination daily (calf tenderness, swelling)
• Low threshold for Doppler ultrasound if suspicion

Pain Management

Neuropathic pain occurs in 50-70% and is often severe and undertreated. [32,33]

Pharmacological Options:

• First-line: Gabapentin 300-3600 mg/day (start 300 mg TDS, titrate) or Pregabalin 150-600 mg/day
• Second-line: Amitriptyline 10-75 mg nocte (if no autonomic instability), Duloxetine 60 mg daily
• Adjunct: Paracetamol, NSAIDs
• Opioids: Morphine, oxycodone (if severe; use cautiously in respiratory compromise)

Non-Pharmacological:

• Physiotherapy, positioning
• Transcutaneous electrical nerve stimulation (TENS)

Pressure Ulcer Prevention

Immobile patients are at high risk for pressure injuries.

Interventions:

• Pressure-redistributing mattress (alternating pressure or low-air-loss)
• Frequent repositioning (every 2 hours)
• Skin inspection daily
• Moisture management (incontinence care)
• Nutrition optimization (albumin, vitamin C, zinc)

Contracture Prevention

Prolonged immobility leads to joint contractures, limiting recovery.

Interventions:

• Passive range-of-motion exercises (physiotherapy 2-3 times daily)
• Splinting (ankle-foot orthoses to prevent foot drop)
• Early mobilization when able

Nutrition

Enteral Nutrition:

• Oral feeding if swallow safe (speech therapy assessment)
• Nasogastric tube if dysphagia or unable to meet needs orally
• Percutaneous endoscopic gastrostomy (PEG) if prolonged dysphagia (> 2-4 weeks)

Caloric Requirements:

• Hypermetabolic state: 25-30 kcal/kg/day
• Protein 1.2-1.5 g/kg/day

Monitoring:

• Weekly weight
• Albumin, prealbumin (markers of nutrition)

Psychological Support

GBS is psychologically traumatic (sudden paralysis, ICU stay, prolonged recovery).

Interventions:

• Reassurance: Emphasize that most patients recover
• Communication aids (if intubated): Eye blink, alphabet board
• Antidepressants if depression develops (SSRIs)
• Post-ICU follow-up for PTSD screening
• Peer support groups

Rehabilitation

Acute Phase (ICU/Ward):

• Passive range-of-motion exercises
• Prevention of contractures
• Positioning

Recovery Phase:

• Active-assisted and active exercises as strength returns
• Gait retraining, balance exercises
• Occupational therapy for ADLs
• Orthotic devices (AFOs, wrist splints)

Outpatient Phase:

• Continuation of physiotherapy (may require 6-12 months)
• Return-to-work planning
• Driving assessment
• Fatigue management (common residual symptom)

---

9. Complications

Complications of GBS arise from the disease itself, prolonged ICU stay, and treatment. Anticipation and prevention are key. [5,6]

Disease-Related Complications

Immobility-Related Complications

Treatment-Related Complications

IVIg Complications:

• Thromboembolism (stroke, MI, DVT): 1-5%
• Acute renal failure: 1-10% (higher with sucrose-stabilized products)
• Aseptic meningitis: 1-3%
• Hemolysis: Rare

Plasma Exchange Complications:

• Hypotension: 5-10%
• Catheter-related infection: 5-10%
• Bleeding: 2-5%
• Allergic reactions: 3-5%

ICU-Related Complications

• Ventilator-associated pneumonia (VAP): 30-50% of ventilated patients
• Delirium: 50-70% of ICU patients
• Critical illness polyneuropathy/myopathy: 10-30% (superimposed on GBS; prolongs recovery)
• Post-traumatic stress disorder (PTSD): 20-40% post-ICU

Chronic Complications and Residual Disability

• Persistent fatigue: 60-80% at 1 year
• Residual weakness: 20-30% at 1 year
• Neuropathic pain: 10-20% chronic
• Foot drop: 5-15% (may require AFO long-term)
• Areflexia: Persists in most patients even after full motor recovery

---

10. Prognosis and Outcomes

The majority of GBS patients achieve functional recovery, though the time course is variable and a significant minority experience residual deficits. [5,6]

Recovery Timeline

Typical Course:

• Progression phase: 1-4 weeks (median 2 weeks)
• Plateau phase: 1-4 weeks
• Recovery phase: 3-12 months (occasionally up to 2 years)

Recovery Pattern:

• Proximal muscles recover before distal
• Lower limbs recover before upper limbs
• Recovery mirrors progression in reverse (descending)

Mortality

Despite advances in ICU care, GBS carries a mortality of 3-7%, primarily due to:

• Respiratory failure with complications (ARDS, VAP, sepsis)
• Sudden cardiac death (autonomic dysfunction)
• Pulmonary embolism
• Sepsis (nosocomial infections)

Risk Factors for Mortality:

• Age > 60 years
• Rapid progression (less than 7 days to nadir)
• Mechanical ventilation required
• Severe autonomic dysfunction
• Axonal subtype (AMAN, AMSAN)

Functional Outcomes

At 1 Year:

• 15-20%: Full recovery (Hughes grade 0)
• 60-65%: Minor residual symptoms but independent (Hughes grade 1)
• 10-15%: Able to walk with assistance (Hughes grade 2-3)
• 5-10%: Unable to walk independently (Hughes grade 4)
• 3-7%: Dead (Hughes grade 6)

Residual Symptoms:

• Persistent fatigue (60-80%): Most disabling long-term symptom
• Weakness (20-30%): Typically distal (foot drop, hand weakness)
• Neuropathic pain (10-20%)
• Areflexia (80-90%): Does not correlate with functional impairment

Prognostic Factors

Poor Prognostic Factors (Predict Inability to Walk at 6 Months):

• Age > 60 years
• Rapid progression (less than 7 days to nadir)
• Mechanical ventilation required
• Preceding diarrheal illness (Campylobacter-associated)
• Severe motor deficit at nadir (Hughes grade 5)
• Low distal CMAP amplitudes on NCS (less than 20% of normal)
• Axonal subtype (AMAN, AMSAN)

Good Prognostic Factors:

• Young age (less than 40 years)
• Gradual progression (> 14 days to nadir)
• Miller Fisher variant
• Demyelinating subtype (AIDP)
• Early initiation of immunotherapy

Recurrence and CIDP

Recurrence:

• Recurrent GBS occurs in 2-5% of patients
• Typically milder than initial episode
• May indicate misdiagnosis (actually CIDP with acute exacerbations)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):

• 5-10% of GBS patients develop CIDP (chronic relapsing form)
• Definition: Progression beyond 8 weeks OR recurrent episodes
• CIDP requires long-term immunosuppression (steroids, IVIg, azathioprine) rather than single-course treatment

Differentiation:

• GBS: Monophasic, nadir within 4 weeks, single treatment course
• CIDP: Progressive > 8 weeks OR relapsing-remitting, requires ongoing treatment

---

11. Prevention and Vaccination

Primary Prevention

No specific measures prevent GBS as the triggers (infections) are ubiquitous. General measures include:

• Hand hygiene to reduce infection transmission
• Food safety (reduce Campylobacter exposure from undercooked poultry)
• Vaccination against triggering infections (influenza, though vaccine itself carries minimal GBS risk)

Vaccination and GBS Risk

Historical Context: The 1976 swine flu vaccine (A/New Jersey/76) was associated with a 7-10 fold increased risk of GBS (approximately 1 case per 100,000 vaccinations), leading to program suspension. [19]

Modern Vaccines: Extensive post-marketing surveillance of seasonal influenza vaccines shows minimal risk:

• Absolute risk: 1-2 cases per 1,000,000 doses
• Risk of GBS after influenza infection: 4-7 per 1,000,000 infections (higher than vaccine)
• Conclusion: Benefits of vaccination outweigh minimal GBS risk [20]

Other Vaccines:

• COVID-19 vaccines (mRNA, viral vector): Case reports exist but no confirmed causal association; background rate indistinguishable from expected incidence
• MMR, DTP, HPV: No convincing evidence of increased GBS risk
• Rabies, meningococcal, hepatitis: Rare case reports; causality unproven

Vaccination in GBS Survivors:

• Prior GBS is NOT an absolute contraindication to vaccination
• Risk of recurrent GBS post-vaccination appears very low (less than 5%)
• Decision individualized; benefits typically outweigh risks (e.g., influenza vaccine in elderly)

---

12. Key Guidelines and Evidence

Major Clinical Practice Guidelines

Landmark Clinical Trials

1. Dutch GBS Study Group (1992):

• Randomized trial: IVIg vs. Plasma Exchange
• Result: Equivalent efficacy; established IVIg as first-line therapy
• Citation: van der Meché FG, et al. N Engl J Med. 1992;326:1123-1129. [49]

2. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial (1997):

• Compared plasma exchange alone, IVIg alone, and both combined
• Result: No benefit of combination therapy over either alone
• Citation: Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349:225-230. [52]

3. Cochrane Review: Corticosteroids for GBS (2016):

• Meta-analysis of 6 RCTs (587 patients)
• Result: No benefit of corticosteroids; possible harm
• Conclusion: Do not use steroids in GBS
• Citation: Hughes RA, et al. Cochrane Database Syst Rev. 2016;(10):CD001446. [54]

4. IVIg vs. Plasma Exchange in Children (2020):

• Pediatric RCT: 237 children
• Result: Equivalent efficacy; IVIg preferred due to ease
• Citation: Korinthenberg R, et al. Lancet Neurol. 2020;19:324-333. [60]

---

13. Examination Focus

Common MRCP/Neurology Exam Questions

1. "What is the diagnostic finding on lumbar puncture in GBS?"

• Answer: Albuminocytologic dissociation—elevated CSF protein (> 0.55 g/L) with normal white cell count (less than 10 cells/µL). Protein elevation develops after the first week in 80-90% of cases. High cell count (> 50/µL) suggests alternative diagnosis (e.g., Lyme, HIV, lymphoma) unless patient is HIV-positive.

2. "What is the triad of Miller Fisher Syndrome?"

• Answer: Ophthalmoplegia, ataxia, areflexia. Associated with anti-GQ1b antibodies in > 85% of cases. Excellent prognosis with self-limited course; immunotherapy often not required.

3. "What is the most important bedside monitoring test for respiratory function in GBS?"

• Answer: Forced vital capacity (FVC) measured by bedside spirometry every 4-6 hours. Pulse oximetry is a late and unreliable marker. FVC less than 20 mL/kg indicates high risk; less than 15 mL/kg mandates intubation. Single breath count less than 15 suggests FVC less than 1L.

4. "What is the role of corticosteroids in GBS management?"

• Answer: No role. Multiple RCTs and Cochrane meta-analyses demonstrate that oral or IV corticosteroids provide no benefit and may delay recovery. Do not use. [54]

5. "Which infection is most strongly associated with GBS?"

• Answer: Campylobacter jejuni (25-40% of cases). Associated with axonal variants (AMAN) and worse prognosis due to molecular mimicry between bacterial lipo-oligosaccharides and GM1 ganglioside. Other triggers include CMV, EBV, Mycoplasma, Zika virus, and influenza.

6. "What is the treatment threshold for immunotherapy?"

• Answer: Hughes Functional Grade ≥3 (unable to walk 5 meters independently). Options are IVIg (2 g/kg over 5 days) or plasma exchange (5 sessions); both equally effective. Combining them provides no benefit.

7. "What nerve conduction study finding is seen earliest in GBS?"

• Answer: Prolonged or absent F-waves. F-waves reflect proximal nerve conduction and are sensitive to early demyelination in nerve roots. Later findings include prolonged distal latencies, slowed conduction velocities, and conduction block (demyelinating subtype) or reduced CMAP amplitudes (axonal subtype).

8. "Name three poor prognostic factors in GBS."

• Answer:
  1. Age > 60 years
  2. Rapid progression (less than 7 days to nadir)
  3. Need for mechanical ventilation
  4. Preceding diarrheal illness (Campylobacter)
  5. Low distal CMAP amplitudes on NCS (Any three acceptable)

Viva Voce Points

Opening Statement: "Guillain-Barré Syndrome is an acute, immune-mediated polyneuropathy characterized by progressive, symmetric, ascending weakness with areflexia. It is the most common cause of acute flaccid paralysis worldwide, with an incidence of 1-2 per 100,000. The syndrome typically follows an infection (Campylobacter jejuni being the most common) by 1-4 weeks and results from molecular mimicry, where antibodies against microbial antigens cross-react with peripheral nerve gangliosides, causing demyelination or axonal injury." [1,2,3]

Subtypes to Mention:

• AIDP (Acute Inflammatory Demyelinating Polyneuropathy): Classic demyelinating form, 85-90% in Western populations, good prognosis
• AMAN (Acute Motor Axonal Neuropathy): Axonal injury, 30-65% in Asia, worse prognosis
• AMSAN (Acute Motor and Sensory Axonal Neuropathy): Severe axonal variant, poorest prognosis
• Miller Fisher Syndrome: Ophthalmoplegia, ataxia, areflexia; anti-GQ1b antibodies; excellent prognosis [11,12,25]

Diagnostic Criteria (Brighton Level 1):

1. Bilateral flaccid weakness
2. Decreased/absent reflexes
3. Progression over days to 4 weeks
4. CSF albuminocytologic dissociation
5. NCS features consistent with demyelination or axonal injury
6. Exclusion of other causes [39]

Management Priorities:

1. Monitoring: Admit all patients; ICU if FVC less than 20 mL/kg, bulbar dysfunction, or autonomic instability
2. Immunotherapy: IVIg (2 g/kg over 5 days) or plasma exchange (5 sessions) for Hughes grade ≥3; equally effective [49,50]
3. Respiratory support: Serial FVC monitoring, elective intubation if less than 15-20 mL/kg [37,38]
4. Autonomic monitoring: Continuous cardiac telemetry; treat arrhythmias/labile BP cautiously
5. Complication prevention: VTE prophylaxis (LMWH), pressure ulcer prevention, pain management
6. Rehabilitation: Early physiotherapy, gradual mobilization

Evidence Base:

• Dutch GBS Study: IVIg equivalent to plasma exchange [49]
• Cochrane Review: Corticosteroids ineffective and harmful [54]
• Mortality 3-7%; 80-85% achieve functional recovery by 1 year [5,6]

Common Mistakes in Exams

❌ Mistakes that fail candidates:

1. Ordering MRI spine routinely: Not needed unless red flags (sensory level, UMN signs, back pain)
2. Starting corticosteroids: Explicitly contraindicated; no benefit, possible harm
3. Missing respiratory monitoring: Stating "monitor oxygen saturations" instead of "serial FVC measurements"
4. Waiting for hypoxia before intubating: FVC thresholds guide intubation, not ABG
5. Combining IVIg and plasma exchange: No additional benefit; wastes resources
6. Not checking for sensory level: Presence of sensory level excludes GBS (suggests myelopathy)
7. Expecting hyperreflexia: GBS causes areflexia; brisk reflexes exclude diagnosis
8. Forgetting autonomic complications: Autonomic dysfunction is common (60-70%) and potentially fatal
9. Not mentioning VTE prophylaxis: High-risk patients; LMWH mandatory
10. Confusing GBS and CIDP: GBS is monophasic (nadir less than 4 weeks); CIDP is chronic/relapsing (> 8 weeks)

Model Answers for Structured Scenarios

Q: A 45-year-old man presents with 5 days of progressive leg weakness ascending to involve his arms. He had diarrhea 2 weeks ago. On examination, he has flaccid paralysis with areflexia. Describe your immediate management.

Model Answer:

"This presentation is highly suggestive of Guillain-Barré Syndrome following Campylobacter gastroenteritis. My immediate priorities are:

1. Assess Severity and Triage:

• Determine Hughes Functional Grade (can he walk 5 meters independently?)
• Respiratory assessment: Forced Vital Capacity (FVC) measurement, single breath count, assess bulbar function (dysphagia, dysphonia)
• Autonomic assessment: Heart rate variability, blood pressure, orthostatic changes
• Decision: ICU admission if FVC less than 20 mL/kg, bulbar dysfunction, Hughes grade ≥4, or autonomic instability

2. Confirm Diagnosis:

• Lumbar puncture: Expect albuminocytologic dissociation (elevated protein, normal WCC), though protein may be normal in first week
• Nerve conduction studies: Will show demyelinating or axonal features; F-wave abnormalities appear early
• Bloods: FBC, U&E, LFTs, CK (exclude myositis), anti-ganglioside antibodies (anti-GM1 given Campylobacter history)

3. Initiate Immunotherapy:

• If Hughes grade ≥3 (unable to walk independently): Start IVIg 2 g/kg over 5 days (0.4 g/kg/day) OR plasma exchange 5 sessions
• Both equally effective; IVIg preferred in most centers due to ease of administration
• Do NOT use corticosteroids (no benefit, possible harm)

4. Respiratory Monitoring:

• Serial FVC measurements every 4-6 hours
• Negative inspiratory force (NIF) monitoring
• Elective intubation if FVC less than 15-20 mL/kg or bulbar dysfunction with aspiration risk
• Avoid succinylcholine for intubation (use rocuronium)

5. Supportive Care:

• VTE prophylaxis: LMWH (enoxaparin 40 mg SC daily) + compression stockings
• Cardiac telemetry (monitor for arrhythmias from autonomic dysfunction)
• Pain management: Gabapentin or pregabalin for neuropathic pain
• Nutrition: Dysphagia screen; NG tube if unsafe swallow
• Pressure ulcer prevention, physiotherapy

6. Prognosis:

• Given Campylobacter association, likely axonal subtype (AMAN) with potentially prolonged recovery
• 80-85% achieve functional recovery by 1 year, though may have residual fatigue/weakness
• Erasmus GBS Outcome Score can guide prognostic counseling

I would involve neurology, ICU, and physiotherapy early."

---

14. Clinical Pearls and High-Yield Mnemonics

Clinical Pearls

Pearl 1: Areflexia is Non-Negotiable If a patient has profound weakness but preserved or brisk reflexes, it is NOT GBS. Think spinal cord compression (UMN signs, sensory level) or myasthenia gravis (fluctuating weakness, ocular involvement). GBS causes universal areflexia early due to afferent limb disruption of the reflex arc. [1,2]

Pearl 2: FVC Trumps Pulse Oximetry Oxygen saturation is a late and insensitive marker of respiratory compromise in GBS. Patients maintain normal SpO₂ until severe hypoventilation occurs. Serial bedside spirometry (FVC, NIF) detects impending failure hours to days before desaturation. FVC less than 20 mL/kg = ICU, less than 15 mL/kg = intubate. [37,38]

Pearl 3: Single Breath Count = Bedside FVC Surrogate Ask the patient to take a deep breath and count aloud as far as possible. If they cannot reach 15, their FVC is likely less than 1L and intubation is imminent. Simple, requires no equipment, highly sensitive. [38]

Pearl 4: Campylobacter = Worse Prognosis Preceding diarrheal illness (Campylobacter jejuni) is associated with axonal variants (AMAN, AMSAN) due to anti-GM1 antibodies. Axonal injury requires slow nerve regeneration (vs. faster remyelination in AIDP), leading to prolonged recovery and higher residual disability. [14,15,23]

Pearl 5: Autonomic Storms Can Kill 60-70% of GBS patients have autonomic dysfunction, manifesting as labile BP and cardiac arrhythmias. Tracheal suctioning, repositioning, or bowel movements can trigger sudden bradycardia or asystole via vagal stimulation. Minimize stimulation in high-risk patients; have atropine at bedside. [35,36]

Pearl 6: Pain is Underrecognized 50-70% of GBS patients have severe neuropathic pain (deep aching in back, thighs, calves), often preceding weakness. This is frequently undertreated. Gabapentin, pregabalin, or amitriptyline (if no autonomic instability) are effective. Opioids may be needed but avoid in respiratory compromise. [32,33]

Pearl 7: Steroids are Useless (and Harmful) Unlike most autoimmune diseases, corticosteroids have NO role in GBS. Multiple RCTs show no benefit and possible harm (delayed recovery, infections). This is a high-yield exam point—know it cold. [54,55]

Pearl 8: Don't Combine IVIg and Plasma Exchange Plasma Exchange/Sandoglobulin GBS Trial definitively showed that combining IVIg and plasma exchange provides no benefit over either alone. Use one or the other, not both. Save resources and avoid unnecessary complications. [52]

Pearl 9: Sensory Level = Not GBS If you find a dermatomal sensory level (e.g., loss of sensation below T10), the diagnosis is NOT GBS. It is a myelopathy (cord compression, transverse myelitis). Order urgent MRI spine within hours. GBS causes glove-and-stocking paresthesias, not a sensory level. [1,2]

Pearl 10: Miller Fisher is Benign Miller Fisher Syndrome (ophthalmoplegia, ataxia, areflexia, anti-GQ1b antibodies) has an excellent prognosis. Most patients recover spontaneously within 3-6 months without immunotherapy, though IVIg may hasten recovery. Reassure patients. [25,26]

Mnemonics

"PARALYZE" for GBS Clinical Features:

• Progressive weakness (ascending)
• Areflexia (universal)
• Respiratory failure (25-30%)
• Autonomic dysfunction (60-70%)
• Lumbar puncture: High protein, Low cells
• Younger or older (bimodal age distribution)
• Zika/infection precedes (60-70%)
• Early treatment (IVIg/PLEX within 2 weeks)

"CAMPYLOBACTER" for Poor Prognostic Factors:

• Campylobacter-associated (preceding diarrhea)
• Age > 60 years
• Mechanical ventilation required
• Progression rapid (less than 7 days to nadir)
• Young CMAPs (low amplitudes on NCS)
• Low functional grade (Hughes 5)
• Older age (repeat for emphasis)
• Bulbar involvement
• Axonal subtype (AMAN/AMSAN)
• Cardiac arrhythmias/autonomic instability
• Time to treatment delay
• Erasmus score high
• Respiratory compromise early

"FVC 20-30-40" Rule:

• FVC less than 20 mL/kg → ICU admission
• NIF < -30 cmH₂O → Intubation
• PaO₂ less than 40 mmHg → Hypoxemic failure (late)

---

15. Patient and Layperson Explanation

What is Guillain-Barré Syndrome?

Guillain-Barré Syndrome, often called GBS, is a condition where your body's immune system (which normally fights infections) mistakenly attacks your own nerves. This happens after you've had an infection like a cold, flu, or stomach bug. The immune system gets "confused" and damages the protective covering around your nerves, similar to how damaged insulation on an electrical wire prevents electricity from flowing properly.

Why Do I Feel Weak?

Your nerves are like electrical cables that carry signals from your brain to your muscles, telling them to move. When the nerves are damaged by your immune system, the signals can't get through properly. This causes your muscles to become weak, usually starting in your legs and moving upward to your arms and sometimes your face. You may also lose the ability to feel things normally or experience tingling and numbness.

Is It Permanent?

For most people, no. GBS is usually a "one-time" illness. Your body can repair the damaged nerves, but this takes time—often weeks to months. About 80-85 out of 100 people recover fully or have only minor remaining problems after a year. However, recovery is slow and requires patience and rehabilitation.

What is the Treatment?

There are two main treatments that work equally well:

1. Intravenous Immunoglobulin (IVIg): This is a solution made from antibodies donated by thousands of healthy people. It's given through a drip into your vein over 5 days. It helps "calm down" your immune system and stops it from attacking your nerves further.

2. Plasma Exchange (Plasmapheresis): This is like "cleaning" your blood. A machine removes your blood, filters out the harmful antibodies that are attacking your nerves, and returns the clean blood to your body. This is done 5 times over about 2 weeks.

Both treatments help you recover faster and reduce the severity of weakness.

Why Am I in the ICU or Hospital?

GBS can affect the muscles you use to breathe. About 1 in 4 people with GBS need help breathing from a machine (ventilator) for a while. Doctors monitor your breathing very closely using a test called forced vital capacity (FVC), which measures how much air you can blow out. If your breathing muscles get too weak, you'll be put on a breathing machine temporarily until your nerves start to recover.

GBS can also affect your heart rate and blood pressure, causing sudden changes. That's why you're on a heart monitor.

Will I Walk Again?

Yes, most likely. About 75-85 out of 100 people are walking independently again by 6 months. Recovery happens in the reverse order of how the weakness started—so if your legs were affected first, they'll usually recover first. Physiotherapy (physical therapy) is very important to help your muscles get strong again and prevent stiffness.

What Caused This?

GBS is usually triggered by an infection you had 1-4 weeks before you became weak. The most common triggers are:

• Stomach infections (like Campylobacter from undercooked chicken)
• Respiratory infections (like flu or colds)
• Viruses like Epstein-Barr virus, cytomegalovirus, or Zika virus

GBS is not contagious—you can't "catch it" from someone else or give it to others. It's your immune system's response to the infection, not the infection itself.

Can It Come Back?

Recurrence is very rare—only about 2-5 out of 100 people get GBS again. For most, it's a one-time event.

What About Vaccinations?

You may have heard that vaccines can cause GBS. This is extremely rare. The risk of GBS after a flu vaccine, for example, is about 1 in 1 million doses, while the risk of GBS after getting the actual flu is much higher (about 4-7 in 1 million infections). The benefits of vaccines far outweigh the tiny risk.

What Can I Expect Long-Term?

Most people recover well, but some experience:

• Fatigue: Feeling tired more easily, even after full strength returns
• Minor weakness: Especially in feet or hands
• Numbness or tingling: Usually mild and improves over time

These residual symptoms can be managed with ongoing physiotherapy, occupational therapy, and supportive care.

Support and Resources

GBS can be frightening and isolating. Consider connecting with:

• GBS/CIDP Foundation International: www.gbs-cidp.org (Patient support, information, forums)
• Local support groups: Ask your healthcare team for referrals
• Counseling: Many people benefit from talking to a psychologist about their experience

Remember: You are not alone, and most people do recover.

---

16. References

1. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. doi:10.1038/s41582-019-0250-9

2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1

3. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-2304. doi:10.1056/NEJMra1114525

4. Kusunoki S, Kaida K. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2011;223(1-2):5-12. doi:10.1016/j.jneuroim.2010.02.001

5. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133. doi:10.1159/000324710

6. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469-482. doi:10.1038/nrneurol.2014.121

7. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33-43. doi:10.1093/brain/awt285

8. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-163. doi:10.1159/000184748

9. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70(18):1608-1613. doi:10.1212/01.wnl.0000310983.38724.d4

10. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14(4):310-315. doi:10.1111/j.1529-8027.2009.00243.x

11. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 ( Pt 3):597-605. doi:10.1093/brain/118.3.597

12. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998;44(5):780-788. doi:10.1002/ana.410440512

13. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-1115. doi:10.1212/wnl.51.4.1110

14. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998;11(3):555-567. doi:10.1128/CMR.11.3.555

15. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A. 2004;101(31):11404-11409. doi:10.1073/pnas.0402391101

16. Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52(7):837-844. doi:10.1093/cid/cir074

17. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539. doi:10.1016/S0140-6736(16)00562-6

18. Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med. 2016;375(16):1513-1523. doi:10.1056/NEJMoa1605564

19. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110(105-123. doi:10.1093/oxfordjournals.aje.a112795

20. Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis. 2013;13(9):769-776. doi:10.1016/S1473-3099(13)70104-X

21. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125(Pt 12):2591-2625. doi:10.1093/brain/awf272

22. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31(6):677-679. doi:10.1002/ana.410310619

23. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39(1):17-28. doi:10.1002/ana.410390105

24. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333-342. doi:10.1002/ana.410330402

25. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56(8):1104-1106. doi:10.1212/wnl.56.8.1104

26. Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2014;85(3):339-344. doi:10.1136/jnnp-2013-305397

27. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64(10):1519-1523. doi:10.1001/archneur.64.10.1519

28. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126(Pt 10):2279-2290. doi:10.1093/brain/awg233

29. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131(Pt 5):1197-1208. doi:10.1093/brain/awm316

30. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326(17):1130-1136. doi:10.1056/NEJM199204233261706

31. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781-787. doi:10.1002/ana.21976

32. Ruts L, Rico R, van Koningsveld R, et al. Pain accompanies pure motor Guillain-Barré syndrome. J Peripher Nerv Syst. 2008;13(4):305-306. doi:10.1111/j.1529-8027.2008.00191.x

33. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology. 1997;48(2):328-331. doi:10.1212/wnl.48.2.328

34. Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia. Arch Neurol. 1994;51(7):671-675. doi:10.1001/archneur.1994.00540190055013

35. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994;17(10):1145-1155. doi:10.1002/mus.880171004

36. Flachenecker P. Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis. J Neurol. 2007;254 Suppl 2:II96-II101. doi:10.1007/s00415-007-2015-7

37. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):893-898. doi:10.1001/archneur.58.6.893

38. Sharshar T, Chevret S, Bourdain F, Raphaël JC; French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003;31(1):278-283. doi:10.1097/00003246-200301000-00047

39. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599-612. doi:10.1016/j.vaccine.2010.06.003

40. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 Suppl:S21-S24. doi:10.1002/ana.410270707

41. Haldeman D, Zulkosky K, Kelley R, Keegan J, Rosenfeld M. Diagnostic value of cerebrospinal fluid protein in Guillain-Barré syndrome. Neurol Clin Pract. 2014;4(2):143-147. doi:10.1212/CPJ.0000000000000015

42. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):913-917. doi:10.1001/archneur.58.6.913

43. Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123(8):1487-1495. doi:10.1016/j.clinph.2012.01.025

44. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47(3):813-817. doi:10.1212/wnl.47.3.813

45. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750-753. doi:10.1016/s0140-6736(78)92644-2

46. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;2014(9):CD002063. doi:10.1002/14651858.CD002063.pub6

47. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6(7):589-594. doi:10.1016/S1474-4422(07)70130-8

48. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76(11):968-975. doi:10.1212/WNL.0b013e3182104407

49. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326(17):1123-1129. doi:10.1056/NEJM199204233261705

50. Hughes RA, Wijdicks EF, Barohn R, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-740. doi:10.1212/wnl.61.6.736

51. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;2012(7):CD001798. doi:10.1002/14651858.CD001798.pub2

52. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225-230. PMID: 9014908

53. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;(2):CD001798. doi:10.1002/14651858.CD001798

54. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10(10):CD001446. doi:10.1002/14651858.CD001446.pub5

55. van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA; Dutch GBS Study Group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004;363(9404):192-196. doi:10.1016/S0140-6736(03)15324-X

56. Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barré syndrome in preschool children. Neurology. 2011;76(9):807-810. doi:10.1212/WNL.0b013e31820e7b62

57. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939-950. doi:10.1016/S1474-4422(08)70215-1

58. Association of British Neurologists. Guidelines on the Use of Intravenous Immunoglobulin in Neurological Diseases. 2018. Available at: https://www.theabn.org/page/ivig_guidelines

59. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34(3):171-354. doi:10.1002/jca.21705

60. Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al; German PIND Study Group. Diagnosis and Treatment of Guillain-Barré Syndrome in Childhood and Adolescence: An Evidence- and Consensus-Based Guideline. Eur J Paediatr Neurol. 2020;25:5-16. doi:10.1016/j.ejpn.2019.10.006

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to current local and international guidelines for the most up-to-date recommendations.